Clinical Trials Browser

Phase 3 × INDUSTRY × Gefitinib × Clear all

Carcinoma, Non-Small-Cell Lung

NCT02296125 2026-01-09

FLAURA

Phase 3 Completed

674 enrolled 21 charts 1 FDA

Thoracic

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer

NCT03787992 2025-04-11

Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）

Phase 3 Active not recruiting

358 enrolled

Thoracic

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer

NCT02588261 2024-12-10

SOLAR

Phase 3 Terminated

530 enrolled 25 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04248829 2024-12-03

Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

Phase 3 Active not recruiting

393 enrolled 13 charts

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

NCT04143607 2024-06-14

ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC

Phase 3 Active not recruiting

337 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01774721 2023-11-14

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

Phase 3 Completed

452 enrolled 35 charts 1 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT03849768 2023-01-20

A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients

Phase 3 Unknown

429 enrolled 18 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03529084 2019-11-22

Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations

Phase 3 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01017874 2015-07-08

A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer

Phase 3 Completed

236 enrolled 15 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00090675 2013-01-29

IMAC/Herbst

Phase 3 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00034879 2013-01-04

Iressa Expanded Access Program (EAP)

Phase 3 Completed

Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

NCT00478049 2012-06-06

ISTANA

Phase 3 Completed

163 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00234468 2011-05-20

Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC

Phase 3 Terminated

490 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00076388 2011-05-13

Iressa Versus Docetaxel (Taxotere)

Phase 3 Completed

1,440 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00206219 2011-01-27

Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX)

Phase 3 Completed

477 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT00635973 2009-04-22

Open-Label Extension of Other SZ1839 (Iressa) Trials

Phase 3 Completed

100 enrolled

Tumor-Agnostic

Neoplasms

NCT00080340 2008-01-15

Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Phase 3 Completed

520 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00252707 2007-12-18

Iressa 2nd Line Phase III Study in Japan

Phase 3 Completed

484 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

RELAY

FLAURA

Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）

SOLAR

Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients

Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations

A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer

IMAC/Herbst

Iressa Expanded Access Program (EAP)

ISTANA

Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC

Iressa Versus Docetaxel (Taxotere)

Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX)

Open-Label Extension of Other SZ1839 (Iressa) Trials

Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Iressa 2nd Line Phase III Study in Japan